Risk of Thromboembolic Events in Patients with Non-Valvular Atrial Fibrillation After Dabigatran or Rivaroxaban Discontinuation – Data from the Ljubljana Registry

Author:

Vene Nina,Mavri Alenka,Gubenšek Mirjam,Tratar Gregor,Vižintin Cuderman Tjaša,Pohar Perme Maja,Blinc AlešORCID

Funder

University Medical Centre Ljubljana

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference24 articles.

1. the RE-LY Steering Committee and Investigators. Dabigatran versus Warfarin in Patients with Atrial Fibrillation;SJ Connolly;N Engl J Med,2009

2. ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation;MR Patel;N Engl J Med,2011

3. The new oral anticoagulants in clinical practice;WI Gonsalves;Mayo Clin Proceed,2013

4. Increased short-term risk of thromboembolism or death after interruption of warfarin treatment in patients with atrial fibrillation;J Raunsø;Eur Heart J,2012

5. Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrialfibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation);MR Patel;J Am Coll Cardiol,2013

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3